Authors' objectives: This health technology assessment looked at the test accuracy, clinical utility, cost-effectiveness, budget impact, and patient experiences of noninvasive prenatal testing (NIPT) for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions.
Noninvasive Prenatal Testing; Sex Chromosome Aneuploidies; Microdeletions; trisomies; cost-effectiveness; patient satisfaction; clinical utility; budget impact analysis; patient experience
10.5
